Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs IPCA LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA IPCA LABS GLENMARK PHARMA/
IPCA LABS
 
P/E (TTM) x -31.5 51.6 - View Chart
P/BV x 2.9 5.4 53.3% View Chart
Dividend Yield % 0.3 0.3 80.5%  

Financials

 GLENMARK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-23
IPCA LABS
Mar-23
GLENMARK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs4871,062 45.9%   
Low Rs349768 45.4%   
Sales per share (Unadj.) Rs460.4243.0 189.5%  
Earnings per share (Unadj.) Rs13.419.4 69.0%  
Cash flow per share (Unadj.) Rs35.029.7 118.0%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Avg Dividend yield %0.60.4 136.8%  
Book value per share (Unadj.) Rs335.1230.3 145.5%  
Shares outstanding (eoy) m282.17253.70 111.2%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.93.8 24.1%   
Avg P/E ratio x31.347.2 66.2%  
P/CF ratio (eoy) x11.930.8 38.7%  
Price / Book Value ratio x1.24.0 31.4%  
Dividend payout %18.720.6 90.6%   
Avg Mkt Cap Rs m117,953232,120 50.8%   
No. of employees `000NANA-   
Total wages/salary Rs m27,81012,876 216.0%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m129,90161,642 210.7%  
Other income Rs m3,1681,518 208.7%   
Total revenues Rs m133,06963,160 210.7%   
Gross profit Rs m15,1259,033 167.4%  
Depreciation Rs m6,1132,616 233.7%   
Interest Rs m3,496482 725.4%   
Profit before tax Rs m8,6857,453 116.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,9112,534 193.8%   
Profit after tax Rs m3,7744,919 76.7%  
Gross profit margin %11.614.7 79.5%  
Effective tax rate %56.534.0 166.3%   
Net profit margin %2.98.0 36.4%  
BALANCE SHEET DATA
Current assets Rs m98,73751,893 190.3%   
Current liabilities Rs m50,45518,058 279.4%   
Net working cap to sales %37.254.9 67.7%  
Current ratio x2.02.9 68.1%  
Inventory Days Days751 13.1%  
Debtors Days Days1156 1,966.5%  
Net fixed assets Rs m76,92034,336 224.0%   
Share capital Rs m282254 111.2%   
"Free" reserves Rs m94,28158,167 162.1%   
Net worth Rs m94,56358,420 161.9%   
Long term debt Rs m38,5216,518 591.0%   
Total assets Rs m175,65886,229 203.7%  
Interest coverage x3.516.5 21.2%   
Debt to equity ratio x0.40.1 365.1%  
Sales to assets ratio x0.70.7 103.4%   
Return on assets %4.16.3 66.1%  
Return on equity %4.08.4 47.4%  
Return on capital %9.212.2 74.9%  
Exports to sales %042.9 0.0%   
Imports to sales %013.3 0.0%   
Exports (fob) Rs mNA26,434 0.0%   
Imports (cif) Rs mNA8,178 0.0%   
Fx inflow Rs m46,46426,434 175.8%   
Fx outflow Rs m12,7128,178 155.5%   
Net fx Rs m33,75118,257 184.9%   
CASH FLOW
From Operations Rs m6,2548,058 77.6%  
From Investments Rs m-5,285-7,250 72.9%  
From Financial Activity Rs m-7755,072 -15.3%  
Net Cashflow Rs m3255,881 5.5%  

Share Holding

Indian Promoters % 46.7 46.3 100.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 34.7 44.8 77.4%  
FIIs % 23.7 10.3 230.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 53.7 99.3%  
Shareholders   209,931 82,809 253.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUN PHARMA    DIVIS LABORATORIES    CIPLA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on Glenmark Pharma vs IPCA Labs

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

Glenmark Pharma vs IPCA Labs Share Price Performance

Period Glenmark Pharma IPCA Labs S&P BSE HEALTHCARE
1-Day -0.38% 3.14% 1.21%
1-Month 5.36% 4.07% -0.72%
1-Year 113.34% 56.18% 61.87%
3-Year CAGR 27.59% 9.39% 18.17%
5-Year CAGR 8.09% 20.83% 19.79%

* Compound Annual Growth Rate

Here are more details on the Glenmark Pharma share price and the IPCA Labs share price.

Moving on to shareholding structures...

The promoters of Glenmark Pharma hold a 46.7% stake in the company. In case of IPCA Labs the stake stands at 46.3%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Glenmark Pharma and the shareholding pattern of IPCA Labs.

Finally, a word on dividends...

In the most recent financial year, Glenmark Pharma paid a dividend of Rs 2.5 per share. This amounted to a Dividend Payout ratio of 18.7%.

IPCA Labs paid Rs 4.0, and its dividend payout ratio stood at 20.6%.

You may visit here to review the dividend history of Glenmark Pharma, and the dividend history of IPCA Labs.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine Sensex Today Rallies 550 Points| Nifty Tops 22,250 | Power Stocks Shine(10:30 am)

Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.